Search

Displaying results 5181 - 5190 of 10000 in total
  1. Drug

    Anzurstobart

    go.drugbank.com/drugs/DB17547
    Investigational

    It is being investigated for cancers. … Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.

  2. Drug

    AMP-201

    go.drugbank.com/drugs/DB18663
    Experimental

    It is under investigation for the treatment of collagen Q congenital myasthenia.

  3. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  4. Drug

    Rose bengal I-131

    go.drugbank.com/drugs/DB09388
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Carob

    go.drugbank.com/drugs/DB10852
    Approved

    Carob allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  7. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.

  8. Drug

    Ebiratide

    go.drugbank.com/drugs/DB20555
    Experimental

    Ebiratide is a small molecule drug. Ebiratide has a monoisotopic molecular weight of 995.53 Da.

    Categories: Pro-Opiomelanocortin
  9. Drug

    Ponazuril

    go.drugbank.com/drugs/DB11452
    ExperimentalVet approved

    Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.

  10. Drug

    CDX-6512

    go.drugbank.com/drugs/DB17841
    Experimental

    CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.